New Strategies in the Treatment of Breast and Gynecologic Cancers

Saturday, March 8, 2014
7:30 am – 12:15 pm
Dana-Farber Cancer Institute
Jimmy Fund Auditorium
Boston, MA

Register Online Now

Agenda | Faculty | CME Credits | Registration | Course Location & Parking

Offered by Dana-Farber/Brigham and Women’s Cancer Center and Harvard Medical School Department of Continuing Education.

Course Overview:

This half-day CME program will update attendees on new strategies in the treatment of breast and gynecologic malignancies. Through lecture and case-based presentations, specialists in the field will discuss current treatment challenges faced by clinicians, including: when to use neoadjuvant therapy in newly diagnosed patients, optimal use of hormonal therapy, and treatment implications for patients with a BRCA1- or BRCA2-related cancer. The course will also focus on the use of genetic tests in the clinical care of oncology patients, including the use of genomic panels and next-generation sequencing for clinical decision-making. This educational activity is designed for oncologists, primary care physicians, gynecologists, nurse practitioners, and other interested clinicians.

Learning Objectives:

At the conclusion of this course, attendees will be able to:

- incorporate neoadjuvant therapy into patient care treatment strategies;
- prescribe hormonal therapy to reduce recurrence risk;
- factor genetic status into treatment decisions;
- utilize genetic tests with appropriate timing, patient populations, and panels; and
- integrate next-generation sequencing into future clinical practice

About the Susan F. Smith Center for Women’s Cancers

As a leader in the world’s fight to end women’s cancers, the Susan F. Smith Center for Women’s Cancers creates powerful possibilities for patients facing breast and gynecologic cancer by bridging the art of compassionate care and the science of clinical research. The Center also provides a wide range of specialized treatment programs and other services – from support groups to complementary therapies – to help meet the diverse needs of women facing cancer.


Agenda:

7:30 am
Registration Check-in and Continental Breakfast

SESSION I: TREATMENT CHALLENGES
Moderator: Ursula A. Matulonis, MD

8:00 am
When to Use Neoadjuvant Therapy in Newly Diagnosed Patients
Ian E. Krop, MD, PhD

8:20 am
Questions and Answers

8:30 am
Update on Optimal Hormonal Therapy
Eric P. Winer, MD

9:00 am
Questions and Answers

9:10 am
Should BRCA1/2 Breast and Gynecologic Cancers be Treated Differently
Panagiotis A. Konstantinopoulos, MD, PhD

9:30 am
Questions and Answers

9:40 am
Challenging Case Presentation and Discussion
Case Presenter: Ursula A. Matulonis, MD
Discussants: Panagiotis A. Konstantinopoulos, MD, PhD; Ian E. Krop, MD, PhD; Eric P. Winer, MD

10:05 am
BREAK

SESSION II: USE OF GENETIC TESTS IN CLINICAL CARE
Moderator: J. Dirk Iglehart, MD

10:20 am
Who and When to Test for Inherited Genes
Beth Overmoyer, MD

10:40 am
Question and Answers

10:50 am
Use of Genetic Panels in Clinical Decision-Making
Michael Hassett, MD, MPH

11:10 am
Question and Answers

11:20 am
The Role of Next Generation Sequencing in Treatment
Nikhil Wagle, MD

11:40 pm
Question and Answers

11:50 am
Challenging Case Presentation and Discussion
Case Presenter: J. Dirk Iglehart, MD
Discussants: Michael Hassett, MD, MPH; Beth Overmoyer, MD; Nikhil Wagle, MD

12:15 pm
Concluding Remarks

ACGME COMPETENCIES: This course is designed to enhance one or more of the following Accreditation Council of Graduate Medical Education competencies: Patient care — Medical knowledge — Practice-based learning and improvement — Systems-based practice.

Faculty

J. Dirk Iglehart, MD
Course Co-Director
Director, Susan F. Smith Center for Women’s Cancers,
Dana-Farber/Brigham and Women’s Cancer Center;
Anne E. Dyson Professor in Women’s Cancers and Surgery,
Charles A Dana Senior Investigator in Cancer Genetics,
Harvard Medical School

Ursula A. Matulonis, MD
Course Co-Director

Medical Director, Gynecologic Oncology, Susan F. Smith Center for Women’s Cancers,
Dana-Farber/Brigham and Women’s Cancer Center;
Associate Professor of Medicine,
Harvard Medical School

Michael Hassett, MD, MPH
Medical Oncologist, Breast Oncology, Susan F. Smith Center for Women’s Cancers,
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine,
Harvard Medical School

Ian E. Krop, MD, PhD
Medical Oncologist, Breast Oncology, Susan F. Smith Center for Women’s Cancers,
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine,
Harvard Medical School

Panagiotis A. Konstantinopoulos, MD, PhD
Medical Oncologist, Gynecologic Oncology, Susan F. Smith Center for Women’s Cancers,
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine,
Harvard Medical School

Beth Overmoyer, MD
Director, Inflammatory Breast Cancer Program, Susan F. Smith Center for Women’s Cancers,
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine,
Harvard Medical School

Nikhil Wagle, MD
Medical Oncologist, Breast Oncology, Susan F. Smith Center for Women’s Cancers,
Dana-Farber/Brigham and Women’s Cancer Center;
Instructor in Medicine,
Harvard Medical School

Eric P. Winer, MD
Chief, Division of Women’s Cancers,
Director, Breast Oncology Center,
Thompson Senior Investigator in Breast Cancer Research,
Susan F. Smith Center for Women’s Cancers,
Dana-Farber/Brigham and Women’s Cancer Center;
Professor of Medicine,
Harvard Medical School

HMS Disclosure Policy:

Harvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS’s policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers, and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

CME Credits:

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of 4.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registration:

Registration fee: $50.00 (non-refundable), includes continental breakfast, course materials, and complimentary parking in the Dana-Farber garage.

Register Online Now

To register by mail, send completed form and check payable to DF/BWCC by February 20, 2014 to the address below:

Women’s Cancers Spring 2014 CME
Attn: Kamira Wooten
Dana-Farber/Brigham and Women’s Cancer Center
450 Brookline Avenue, OS381
Boston, MA 02215

If you have food allergies, or if you require accommodations such as an ASL interpreter, materials in alternative format or wheelchair access, please email kwooten@partners.org or call 800-553-3787.

Course Location and Parking:

This course is being held in the Jimmy Fund Auditorium at Dana-Farber Cancer Institute, located at 35 Binney Street, Boston, MA. Complimentary parking is available for attendees in the Dana-Farber garage. For direction, please visit: www.dana-farber.org/directions.

Take The First Step
Make AN Appointment

Boston, Main Campus
877-332-4294

Online Appointments

South Shore
781-624-5000


MILFORD
877-332-4294

Patient Stories

Read inspiring stories of strength,
hope and perseverance.

© 2014; Dana-Farber/Brigham and Women's Cancer Center, Boston, MA